This definition appears very rarely
and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
See other meanings of APML
We have 18 other definitions for APML
in our Acronym Attic
Samples in periodicals archive:
Important Information about Tretinoin Capsules Tretinoin Capsules are indicated for the induction of remission in patients with acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant), characterized by the presence of the t (15;17) translocation and/or the presence of the PML/RARalpha gene who are refractory to, or who have relapsed from, anthracycline chemotherapy, or for whom anthracycline based chemotherapy is contraindicated.
Introduction Acute promyelocytic leukemia with t(15;17) is a cancerous disease of the white blood cells in the bone marrow and peripheral blood.
One study centered on a 39-year-old woman who appeared to have classic case of acute promyelocytic leukemia (APL), but lacked the usual genetic signs associated with it.
Arsenic trioxide has been used as a mitochondria-targeting drug in acute promyelocytic leukemia (Jimi et al.
Nippon Shinyaku) has launched TRISENOX(R) (arsenic trioxide) in Japan after receiving pricing approval from the Japanese Ministry of Health to market the drug for patients with relapsed or refractory acute promyelocytic leukemia (APL).
Acute promyelocytic leukemia (APL) is caused by inhibition of apoptosis and a block in myeloid differentiation resulting from a translocation invariably involving the retinoic acid a (RAR[alpha]) gene (1,2).
Seattle, WA; 206-282-7100), announced that the European Commission has granted the Marketing Authorization for TRISENOX (arsenic trioxide), indicated for the induction of remission and consolidation in adult patients with relapsed/refractory acute promyelocytic leukemia characterized by the presence of the t(15:17) translocation and/or the presence of the Pro-Myelocytic Leukemia/Retinioic-Acid-Receptor-alpha (PML/RAR-alpha) gene.
In May, the 23-year-old Morariu was diagnosed with acute promyelocytic leukemia and had been receiving chemotherapy treatments.